418 related articles for article (PubMed ID: 24851052)
1. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
Vuorio A; Tikkanen MJ; Kovanen PT
Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
[TBL] [Abstract][Full Text] [Related]
2. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.
Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA
Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461
[TBL] [Abstract][Full Text] [Related]
3. Lomitapide for the management of homozygous familial hypercholesterolemia.
deGoma EM
Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
[TBL] [Abstract][Full Text] [Related]
4. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
[TBL] [Abstract][Full Text] [Related]
5. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
Gouni-Berthold I; Berthold HK
Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
[TBL] [Abstract][Full Text] [Related]
6. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
Stefanutti C
Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
[TBL] [Abstract][Full Text] [Related]
7. Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience.
Aljenedil S; Alothman L; Bélanger AM; Brown L; Lahijanian Z; Bergeron J; Couture P; Baass A; Ruel I; Brisson D; Khoury E; Gaudet D; Genest J
Atherosclerosis; 2020 Oct; 310():54-63. PubMed ID: 32906018
[TBL] [Abstract][Full Text] [Related]
8. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
[TBL] [Abstract][Full Text] [Related]
9. Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
Sanna C; Stéphenne X; Revencu N; Smets F; Sassolas A; Di Filippo M; Descamps OS; Sokal EM
Atherosclerosis; 2016 Apr; 247():97-104. PubMed ID: 26894473
[TBL] [Abstract][Full Text] [Related]
10. Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.
Sirtori CR; Pavanello C; Bertolini S
Ann Med; 2014 Nov; 46(7):464-74. PubMed ID: 24987866
[TBL] [Abstract][Full Text] [Related]
11. Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting.
Mahzari M; Zarif H
Adv Ther; 2021 May; 38(5):2159-2169. PubMed ID: 33829367
[TBL] [Abstract][Full Text] [Related]
12. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
Davis KA; Miyares MA
Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
[TBL] [Abstract][Full Text] [Related]
13. Homozygous familial hypercholesterolaemia: update on management.
France M
Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
[TBL] [Abstract][Full Text] [Related]
14. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
Ito MK; Watts GF
Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
[TBL] [Abstract][Full Text] [Related]
15. Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia.
Walsh MT; Hussain MM
Crit Rev Clin Lab Sci; 2017 Jan; 54(1):26-48. PubMed ID: 27690713
[TBL] [Abstract][Full Text] [Related]
16. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
Bell DA; Hooper AJ; Watts GF; Burnett JR
Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
[TBL] [Abstract][Full Text] [Related]
17. Lomitapide for the treatment of hypercholesterolemia.
Berberich AJ; Hegele RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1261-1268. PubMed ID: 28598687
[TBL] [Abstract][Full Text] [Related]
18. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
Roeters van Lennep J; Averna M; Alonso R
J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
[TBL] [Abstract][Full Text] [Related]
19. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
[TBL] [Abstract][Full Text] [Related]
20. Microsomal transfer protein inhibition in humans.
Cuchel M; Rader DJ
Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]